Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

30 Jun 2017

Abstract excerpt

Extensive interindividual variation in response to chemotherapy is a major stumbling block in achieving desirable efficacy in the treatment of cancers, including multiple myeloma (MM). In this study, our goal was to develop a gene expression signature that predicts response specific to proteasome inhibitor (PI) treatment in MM. Using a well-characterized panel of human myeloma cell lines (HMCLs) representing the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28665416
DOI: 10.1038/bcj.2017.56

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaPMID 28665416Read ↗

A gene expression signature based on cell-death related gene expression in multiple myelomaSemantic proximity Read ↗

A robust gene expression signature to predict proteasome inhibitor benefit in Multiple MyelomaSemantic proximity Read ↗

In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myelomaSemantic proximity Read ↗

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureSemantic proximity Read ↗

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.Semantic proximity Read ↗

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.Semantic proximity Read ↗

Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment.Semantic proximity Read ↗

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibSemantic proximity Read ↗

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaSemantic proximity Read ↗

RNAseq-Based Machine Learning Models for Prognostication of Multiple MyelomaSemantic proximity Read ↗

Unsupervised Multiomics Integration Identifies Prognostic Subtypes and Druggable Vulnerabilities in Multiple MyelomaSemantic proximity Read ↗

Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.